Literature DB >> 26186891

Association of GSTM1, GSTT1, GSTP1-ILE105VAL and ACE I/D polymorphisms with ankylosing spondylitis.

Esra Erkol İnal1, Orhan Görükmez2, Selma Eroğlu3, Özlem Görükmez4, Özlem Solak3, Ali Topak4, Tahsin Yakut4.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown origin. The aim of this study is to clarify the relationships between susceptibility and severity of AS and GST-mu1 (GSTM1), GST-theta1 (GSTT1), GST-pi1 (GSTP1)-Ile105Val and angiotensin-converting enzyme (ACE) I/D polymorphisms in AS patients. One hundred thirty-eight AS patients and seventy-one healthy controls were enrolled in this study. Erythrocyte sedimentation rate and C-reactive protein (CRP) levels of the AS patients were recorded. The scores of the numeric rating scale (NRS) pain, the Bath Ankylosing Spondylitis Activity Index, the Bath Ankylosing Spondylitis Metrology Index and the Bath Ankylosing Spondylitis Functional Index were calculated. The genotypes distributions and allele frequencies of GSTM1, GSTT1, GSTP1-Ile105Val and ACE I/D polymorphisms were compared between patients and healthy controls. The Multiplex polymerase chain reaction (PCR) and the PCR-restriction fragment length polymorphism methods were used to detect the polymorphisms of ACE I/D, the GSTT1 and GSTM1 genes and the GSTP1-Ile105Val polymorphism, respectively. There were significantly higher levels of the GSTT1 null and the ACE II genotypes in AS patients compared to those in healthy controls (p = 0.002 and 0.005, respectively). We found significantly higher levels of CRP and the NRS pain scores in the patients with ACE ID or DD genotypes compared to those in the patients with ACE II genotypes (p = 0.005 and 0.035, respectively). The present results showed that genes involved in protection from oxidative stress and ACE gene may influence disease development and course in AS.

Entities:  

Keywords:  ACE I/D; Disease activity; Disease severity; GSTM1; GSTP1-Ile105Val; GSTT1

Mesh:

Substances:

Year:  2015        PMID: 26186891     DOI: 10.1007/s00296-015-3317-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

Review 1.  Etiopathogenesis of Behcet's disease.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Mario Jiménez-Hernández; Cesar Jiménez Hernández; Carlos Riebeling-Navarro; Arnulfo Nava Zavala; Mauricio Vera Recabarren; Gerard Espinosa; Javier Jara Quezada; Ricard Cervera
Journal:  Autoimmun Rev       Date:  2009-10-30       Impact factor: 9.754

2.  Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis.

Authors:  Brendan T Keenan; Lori B Chibnik; Jing Cui; Bo Ding; Leonid Padyukov; Henrik Kallberg; Camilla Bengtsson; Lars Klareskog; Lars Alfredsson; Elizabeth W Karlson
Journal:  Arthritis Rheum       Date:  2010-11

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Association analysis of TNFR2, VDR, A2M, GSTT1, GSTM1, and ACE genes with rheumatoid arthritis in South Asians and Caucasians of East Midlands in the United Kingdom.

Authors:  Anant M Ghelani; Ash Samanta; Adrian C Jones; Sarabjit S Mastana
Journal:  Rheumatol Int       Date:  2010-04-18       Impact factor: 2.631

5.  Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies.

Authors:  Diaa K Shehab; Khaled F Al-Jarallah; Adel M Al-Awadhi; Adeeba Al-Herz; Ibrahim Nahar; Mohammad Z Haider
Journal:  J Biomed Sci       Date:  2007-08-23       Impact factor: 8.410

6.  Association between the polymorphisms of glutathione S-transferase genes and rheumatoid arthritis: a meta-analysis.

Authors:  Jong Dae Ji; Won Jin Lee
Journal:  Gene       Date:  2013-03-26       Impact factor: 3.688

7.  The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity.

Authors:  Altinay Goksel Karatepe; Yesim Akkoc; Servet Akar; Yesim Kirazli; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-07-10       Impact factor: 2.631

8.  The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis.

Authors:  N Dalbeth; J Edwards; S Fairchild; M Callan; F C Hall
Journal:  Rheumatology (Oxford)       Date:  2004-09-07       Impact factor: 7.580

9.  Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis.

Authors:  P Bohanec Grabar; D Logar; M Tomsic; B Rozman; V Dolzan
Journal:  Clin Exp Rheumatol       Date:  2009 Mar-Apr       Impact factor: 4.473

10.  Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis.

Authors:  Adel M Al-Awadhi; Eman A Hasan; Prem N Sharma; M Zafaryab Haider; Khaled Al-Saeid
Journal:  Rheumatol Int       Date:  2007-04-14       Impact factor: 2.631

View more
  3 in total

1.  RNA-sequencing study of peripheral blood mononuclear cells in sporadic Ménière's disease patients: possible contribution of immunologic dysfunction to the development of this disorder.

Authors:  Y Sun; D Zhang; G Sun; Y Lv; Y Li; X Li; Y Song; J Li; Z Fan; H Wang
Journal:  Clin Exp Immunol       Date:  2017-12-11       Impact factor: 4.330

2.  Association of Glutathione S-Transferase M1 null genotype with inflammatory bowel diseases: A systematic review and meta-analysis.

Authors:  Yu-Jie Zhou; Bao-Lin Zhao; Zheng Qian; Yi Xu; Ya-Qing Ding
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients.

Authors:  Boglárka Soós; Miklós Fagyas; Ágnes Horváth; Edit Végh; Anita Pusztai; Monika Czókolyová; Alexandra Csongrádi; Attila Hamar; Zsófia Pethő; Nóra Bodnár; György Kerekes; Katalin Hodosi; Éva Szekanecz; Szilvia Szamosi; Sándor Szántó; Gabriella Szűcs; Zoltán Papp; Zoltán Szekanecz
Journal:  Front Med (Lausanne)       Date:  2022-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.